Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000766

Drug Information
NameTelmisartan
SynonymsBIDD:GT0365; 144701-48-4; 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid; Abbott brand of telmisartan; YM-086; C084178; NCGC00095150-02; NCGC00095150-03; CHEMBL1017; Spectrum3_001089; GlaxoSmithKline brand of telmisartan; BIBR-277-SE; BIBR 277SE; S1738_Selleck; AC-2013; AC1Q5U7O; BIBR-277SE; HSDB 7590; Bay 68-9291; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid; Spectrum5_001053; Micardis; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid; Boehringer Ingelheim brand of telmisartan; 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; Telmisartan; Pritor; BSPBio_002738; BRD-K73999723-001-02-2; 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid; D00627; C33H30N4O2; Bio-0103; CHEBI:9434; (1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-; Kinzalmono; BAY-68-9291; Telmisartan (JAN/USAN/INN); LS-44263; Glaxo Wellcome brand of telmisartan; SMR000466326; STK624049; I06-0281; HMS2051P16; 4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid; SPECTRUM1505261; BIBR 277; HMS2093M22; Kinzal; 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; BAY68-9291; HMS2090P17; MolPort-003-666-621; NCGC00095150-01; SAM001246602; CPD000466326; CID65999; Spectrum2_001976; BIBR-277; L001035; SPBio_002131; Micardis (TN); Spectrum4_001261; Telmisartan [USAN:INN]; TL8000991; DB00966; MLS001076687; KBioGR_001842; C07710; Micardis, Targit, Temax, BIBR277, Telmisartan; HMS1922P07; AC1L24EB; KBio3_001958; MLS000759432; UNII-U5SYW473RQ
Trade NameMicardis
CompanyBoehringer Ingelheim
IndicationHypertension
[ICD9: 401   ICD10: I10, I11, I12, I13, I15]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27
)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(2
5)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
InChIKeyRMMXLENWKUUMAY-UHFFFAOYSA-N
Canonical SMILESCCCC1=NC2=C(C=C(C=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C5=NC6=CC=CC=
C6N5C)C    
Therapeutic ClassAntihypertensive Agents
CAS NumberCAS 144701-48-4
FormulaC33H30N4O2
PubChem Compound IDCID 65999.
PubChem Substance IDSID 9912.
ChEBI9434;
SuperDrug ATC IDC09CA07
SuperDrug CAS ID144701484;
TargetType-1 angiotensin II receptorAntagonist[2]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35. Epub 2009 Mar 11. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543